Julie Mayo Lamberte
A5082004502- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
- Infection Control and Ventilation
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- COVID-19 Pandemic Impacts
- COVID-19 and healthcare impacts
- Quantum Electrodynamics and Casimir Effect
- Air Quality and Health Impacts
- Per- and polyfluoroalkyl substances research
- Retinal and Optic Conditions
- Viral Infections and Outbreaks Research
- Ethics and Legal Issues in Pediatric Healthcare
- COVID-19 and Mental Health
- Hepatitis C virus research
- Influenza Virus Research Studies
- Respiratory viral infections research
Centers for Disease Control and Prevention
2021-2024
National Center for Immunization and Respiratory Diseases
2024
University of Arizona
2022-2023
Kaiser Permanente
2023
University of Miami
2022
University of Utah
2022
Rocky Mountain University of Health Professions
2022
Computer Emergency Response Team
2021
Saint Luke's Health System
2021
Regional Health
2021
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic randomized placebo-controlled Phase III trials (1,2); however, the benefits of these for asymptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered real-world conditions, is less well understood. Using prospective cohorts health care personnel, first responders, other essential frontline workers* eight U.S....
Information is limited regarding the effectiveness of two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attenuating disease 2019 (Covid-19) when administered real-world conditions.
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) May 12, 2021, and children 5-11 November 2, 2021 (1-4). Real-world data effectiveness (VE) these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant United States December early investigations of VE demonstrated a decline protection against symptomatic...
The Arizona Healthcare, Emergency Response, and Other Essential workers Study (AZ HEROES) aims to examine the epidemiology of SARS-CoV-2 infection COVID-19 illness among adults with high occupational exposure risk.
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the virus that causes COVID-19) randomized placebo-controlled Phase III trials persons aged 12-17 years (referred to as adolescents this report) (1); however, data on real-word effectiveness (VE) among are limited (1-3). As of December 2021, the Pfizer-BioNTech is approved by Food and Drug Administration (FDA) for 16-17 under FDA emergency use authorization those 12-15...
In a cohort of essential workers in the United States previously infected with SARS-CoV-2, risk factors for reinfection included being unvaccinated, infrequent mask use, time since first infection, and non-Hispanic Black. Protecting from requires multipronged approach including up-to-date vaccination, use as recommended, reduction underlying health disparities.
Workers critical to emergency response and continuity of essential services during the COVID-19 pandemic are at a disproportionally high risk SARS-CoV-2 infection. Prospective cohort studies needed for enhancing understanding incidence symptomatic asymptomatic infections, identifying factors, assessing clinical outcomes, determining effectiveness vaccination.The Research on Epidemiology in Essential Response Personnel (RECOVER) prospective study was designed estimate examine factors...
Per- and polyfluoroalkyl substances (PFAS) are ubiquitous throughout the United States. Previous studies have shown PFAS exposure to be associated with a reduced immune response. However, relationship between serum antibody levels following SARS-CoV-2 infection or COVID-19 vaccination has not been examined. We examined differences in peak response longitudinal decline of antibodies by cohort essential workers measured using an in-house semi-quantitative enzyme-linked immunosorbent assay...
In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, occupation, their impact on uptake over time.Initiated in July 2020, the HEROES-RECOVER provided socio-demographics COVID-19 vaccination data. Using two follow-up surveys approximately three months apart, KAP, receipt was collected; first survey categorized participants as reluctant, reachable, or endorser.A total 4,803 were...
<h3>Importance</h3> Understanding the relative risk of SARS-CoV-2 infection across occupations can inform guidance to protect workers and communities. Less is known about for first responders other essential than health care personnel. <h3>Objective</h3> To compare prevaccination incidence among with <h3>Design, Setting, Participants</h3> This was a prospective cohort study personnel, responders, in Arizona from July 20, 2020, March 14, 2021. Participants were seronegative at enrollment, had...
ABSTRACT BACKGROUND Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered real-world conditions. METHODS Prospective cohorts of 3,975 healthcare personnel, first responders, other essential frontline workers completed weekly testing during December 14 2020—April 10 2021. Self-collected mid-turbinate nasal swabs were tested by qualitative...
Abstract Background We sought to evaluate the impact of changes in estimates COVID‐19 vaccine effectiveness on incidence laboratory‐confirmed infection among frontline workers at high risk for SARS‐CoV‐2. Methods analyzed data from a prospective worker cohort estimate by month as well association vaccination, occupation, demographics, physical distancing, and mask use with risk. Participants completed baseline quarterly surveys, each week self‐collected mid‐turbinate nasal swabs reported...
Approximately 12 million children and adolescents aged ≤18 years in the United States have been infected with SARS-CoV-2, virus that causes COVID-19, since December 2019,* COVID-19-associated hospitalization rates increased among <5 during B.1.617.2 (Delta) B.1.1.529(Omicron) variant peaks (1).In June 2022, Food Drug Administration amended Emergency Use Authorization for BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine to include use of 6 months-4 mRNA-1273 (Moderna) months-5 years, which CDC...
Assessing the real-world effectiveness of COVID-19 vaccines and understanding incidence severity SARS-CoV-2 illness in children are essential to inform policy guide health care professionals advising parents caregivers who test positive for SARS-CoV-2.This report describes objectives methods conducting Pediatric Research Observing Trends Exposures Timelines (PROTECT) study. PROTECT is a longitudinal prospective pediatric cohort study designed estimate vaccine (VE) against infection among...
Abstract Background Data on antibody kinetics are limited among individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of healthcare personnel and other frontline workers in 6 US states, we assessed waning after messenger RNA (mRNA) dose response to 3 according SARS-CoV-2 infection history. Methods Participants submitted sera every months, infection, each mRNA vaccine dose. Sera were tested for antibodies reported as area under the...
Pediatric COVID-19 vaccine hesitancy and uptake is not well understood. Among parents of a prospective cohort children aged 6 months-17 years, we assessed knowledge, attitudes, practices (KAP), over 15 months.
While there is evidence that COVID-19 vaccination protects against development of post-COVID conditions (PCC) after severe infection data are limited on whether reduces the risk cases less-severe non-hospitalized disease with more recent SARS-CoV-2 variant viruses. This study assessed was protective subsequent PCC in persons predominantly mild initial infections during both Delta and Omicron predominance.
<sec> <title>BACKGROUND</title> COVID-19 has spread worldwide since late 2019, with an unprecedented case count and death toll globally. Health care personnel (HCP), first responders, other essential frontline workers (OEWs) are at increased risk of SARS-CoV-2 infection because frequent close contact others. </sec> <title>OBJECTIVE</title> The Arizona Healthcare, Emergency Response, Other Essential Workers Study (AZ HEROES) aims to examine the epidemiology illness among adults high...
ABSTRACT Introduction In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, occupation, their impact on uptake over time. Methods Initiated in July 2020, HEROES-RECOVER provided socio-demographics COVID-19 vaccination data. Using follow-up two surveys approximately three months apart, KAP, receipt was collected; the first survey categorized participants as reluctant, reachable, or...
ABSTRACT Law Enforcement Officers (LEOs), firefighters, and other first responders are at increased risk of SARS-CoV-2 infection compared to healthcare personnel but have relatively low COVID-19 vaccine uptake. Resistance mandates among has the potential disrupt essential public services threaten health safety. Using data from HEROES-RECOVER prospective cohorts, we report on illness burden unvaccinated responders. From January September 2021, contributed weekly active surveillance for...
<sec> <title>BACKGROUND</title> Workers critical to emergency response and continuity of essential services during the COVID-19 pandemic are at a disproportionally high risk SARS-CoV-2 infection. Prospective cohort studies needed for enhancing understanding incidence symptomatic asymptomatic infections, identifying factors, assessing clinical outcomes, determining effectiveness vaccination. </sec> <title>OBJECTIVE</title> The Research on Epidemiology in Essential Response Personnel (RECOVER)...